Valuation: Krystal Biotech, Inc.

Market Cap 9.66B 8.36B 7.81B 7.16B 13.47B 920B 13.68B 91.57B 35.94B 461B 36.28B 35.49B 1,524B P/E 2026 *
43.8x
P/E 2027 * 35.1x
Enterprise Value 9.66B 8.36B 7.81B 7.16B 13.47B 920B 13.68B 91.57B 35.94B 461B 36.28B 35.49B 1,524B EV / Sales 2026 *
19.2x
EV / Sales 2027 * 14.8x
Free-Float
87.22%
Yield 2026 *
-
Yield 2027 * -
1 day+1.17%
1 week-4.30%
Current month-4.30%
1 month-13.04%
3 months+6.78%
6 months+19.69%
Current year+32.41%
1 week 297.02
Extreme 297.02
332.3
1 month 297.02
Extreme 297.02
375
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Executive Officer 61 2016-04-14
Chief Operating Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Other

EVP, Head of International

51,478 0.1761%
3/1/26 Other

General Counsel

68,165 0.2332%
2/27/26 Fiscal year

Founder

38,556 0.1330%
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%-4.30%+135.43%+181.69% 9.66B
+1.59%+2.85%+39.32%+0.52% 78.32B
+2.77%+4.78%-0.98%+28.10% 51.1B
-0.84%+0.09%+20.92%+175.02% 49.18B
-0.13%+7.42%-49.33%-50.09% 44.71B
+0.80%+2.46%+59.13%-24.15% 30.72B
+1.84%+0.87%+53.80%+86.83% 24.44B
+9.86%+7.94%+126.53%-40.68% 23.62B
+4.29%+9.40%+3.95%+230.49% 21.05B
+1.66%-3.70%+66.13%+121.72% 16.61B
Average +2.30%+3.24%+45.49%+70.95% 34.94B
Weighted average by Cap. +1.86%+4.05%+29.94%+48.34%

Financials

2026 *2027 *
Net sales 504M 436M 407M 374M 703M 48.01B 714M 4.78B 1.88B 24.06B 1.89B 1.85B 79.55B 655M 566M 529M 485M 913M 62.31B 927M 6.21B 2.44B 31.23B 2.46B 2.4B 103B
Net income 232M 201M 188M 172M 324M 22.09B 329M 2.2B 864M 11.07B 872M 853M 36.61B 307M 266M 248M 228M 428M 29.23B 435M 2.91B 1.14B 14.65B 1.15B 1.13B 48.43B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-07 US$326.45 +1.17% 160,038
26-08-06 US$322.69 -0.95% 206,285
26-08-05 US$325.78 +0.31% 324,612
26-08-04 US$324.77 +3.90% 534,611
26-08-03 US$312.57 -8.37% 1,172,009
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
326.45USD
Average target price
382.86USD
Spread / Average Target
+17.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock